3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Lymphoid
1
Conditions
Breast Neoplasms
12
Neoplasms
4
Recurrence
3
Squamous Cell Carcinoma of Head and Neck
2
Neoplasms by Site
2
Neoplasm Metastasis
2
Head and Neck Neoplasms
2
Endometrial Neoplasms
2
Breast Diseases
2
Brain Neoplasms
2
Uterine Cervical Neoplasms
1
Unilateral Breast Neoplasms
1
Triple Negative Breast Neoplasms
1
Spinal Cord Neoplasms
1
Recurrent Ovarian High Grade Serous Adenocarcinoma
1
Ovarian Neoplasms
1
Neurofibromatosis 1
1
Neoplasms, Squamous Cell
1
Multiple Myeloma
1
Meningioma
1
Lymphoma, Non-Hodgkin
1
Locally Advanced (Inoperable) or Metastatic Breast Cancer
1
Liposarcoma
1
Hereditary Sensory and Autonomic Neuropathies
1
HR+/HER2- Breast Cancer
1
Glioma
1
Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
1
Central Nervous System Neoplasms
1
Central Nervous System Diseases
1
Brain Diseases
1
Interventions
Dexamethasone
46
Lenalidomide
30
Bortezomib
24
daratumumab
23
pomalidomide
20
Cyclophosphamide
16
carfilzomib
15
Specimen Handling
14
Biopsy
14
Calcium Dobesilate
12
isatuximab
11
Magnetic Resonance Spectroscopy
10
talquetamab
9
Melphalan
8
iberdomide
7
fludarabine
7
belantamab mafodotin
6
tocilizumab
5
selinexor
5
dexamethasone acetate
5
dexamethasone 21-phosphate
5
auricularum
5
X-Rays
5
fludarabine phosphate
4
elotuzumab
4
Sirolimus
4
Nuclear Medicine Department, Hospital
4
trametinib
3
dabrafenib
3
Whole-Body Irradiation
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Multiple Myeloma
×
abemaciclib
×
30 days
×
Clear all
NCT02693535
2026-05-29
TAPUR
American Society of Clinical Oncology
Phase 2
Recruiting
4,200 enrolled